The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Ono President Hopes to Turn Deciphera into Black in 2-3 Years
After closing its largest-ever acquisition earlier this year, Ono Pharmaceutical is eager to make its now-subsidiary Deciphera Pharmaceuticals profitable in a few years, President Toichi Takino says. “We hope to be able to achieve a profit (for Deciphera) on a…
To read the full story
Related Article
- Ono’s Sales Rise 7% on Overseas Growth of Qinlock, Romvimza
October 31, 2025
- Ono’s Profits Slide Over 60% as Deciphera Buyout Costs Swell
May 9, 2025
- Ono’s H1 Revenue Falters 7% after Opdivo Price Cuts
November 1, 2024
- Ono Completes Acquisition of Deciphera
June 13, 2024
- Ono Picks Up Deciphera in US$2.4 Billion Deal to Extend Pipeline, Market Channels
May 1, 2024
BUSINESS
- Shionogi to Buy Tanabe’s Edaravone Biz for US$2.5 Billion Upfront
December 23, 2025
- Asahi Kasei to Relocate R&D Base to Shonan iPark in January 2027
December 23, 2025
- Daiichi Begins Global PIII of Enhertu in Adjuvant Endometrial Cancer Use
December 23, 2025
- Enhertu Wins US Breakthrough Tag in Post-Neoadjuvant HER2 Breast Cancer
December 23, 2025
- Teikoku to Market Medipost’s Knee OA Cell Therapy in Japan
December 22, 2025
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…